Asthenia-fatigue syndrome (AFS) is defined as a persistent, subjective sense of tiredness
related to cancer or its treatment and greatly impacts quality of life among cancer patients …

The introduction of targeted therapy represents a major advance in the treatment of tumor
progression. Targeted agents are a novel therapeutic approach developed to disrupt …

Sunitinib is an orally available small-molecule multikinase inhibitor. This agent potently
inhibits the vascular endothelial growth factor receptor, platelet-derived growth factor …

Sunitinib malate is a new reference standard for the treatment of metastatic renal cell
carcinoma (mRCC)[1, 2]. Clinical or biological markers of activity and toxicity are warranted …

3092 Background: Sunitinib is a multi-target tyrosine kinase inhibitor with anti-angiogenic
and anti-proliferative activity mediated by signal blockade of VEGFR1/2, KIT, PDGFRα/β …

Sunitinib malate (Sutent, SU11248) is a small‐molecule multitargeted tyrosine kinase
inhibitor (TKI) used for the treatment of renal cell carcinoma and imatinib‐resistant …

Unanswered questions regarding the management of sunitinib-induced hypothyroidism |
Nature Reviews Clinical Oncology Skip to main content Thank you for visiting nature.com …

Sunitinib, an oral vascular endothelial growth factor receptor, is a first-line option for
metastatic renal cell carcinoma and widely used in clinical practice. Despite the proven …

Abstract Narrow Therapeutic Index Drugs (NTIDs) are characterized by a small range
between therapeutic and toxicological effect. Missing international harmonized definition for …

Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with
malignancies. One such agent, sunitinib (Sutent, Pfizer, New York, NY, USA), has …